Cerebrolisina: what it is and what the evidence says
A peptide preparation studied for its relationship with neurotrophic factors and neuronal protection and function.
Last reviewed: August 16, 2026 · How we verify this
The ground it plays on
The brain adapts by forming and strengthening connections. Neurotransmitters take part in that conversation, along with factors that help neurons survive and grow. Compounds in this group are studied for their relationship with focus, memory, mood or neuroprotection — and it is worth saying plainly that this is the area where claims are most exaggerated and where human evidence is thinnest.
What it is studied for
Cognitive function, neuroprotection, recovery.
There is a distinction that almost always gets lost. A compound being studied for something is not the same as achieving it. And even where it works in a dish or in a mouse, that says little about whether it works in a person or whether the benefit is worth the risk. The section below therefore carries more weight than everything above it.
What the human evidence says
It is the compound in its group with the most clinical trials and Cochrane reviews, but the overall result is disappointing: the 2023 Cochrane review on acute ischemic stroke concludes with moderate certainty that it probably provides no benefit for mortality, and it detects a possible increase in serious non-fatal adverse effects.
The limitation that matters most
Almost every trial with declared funding was sponsored by the manufacturer, and the included studies carry a high risk of bias. Cochrane itself rates the evidence base in vascular dementia as weak, despite non-Cochrane meta-analyses that look favorable.
Regulatory status
Registered in several Eastern European and Asian countries; not approved by the FDA.
Status can change and varies by country. Always verify the rules in force where you live before drawing conclusions.
Cautions and context
Clinically managed; medical context is decisive.
Requires professional assessment and follow-up; not for self-management.
What this page cannot give you
A reference page can take you this far. You know what Cerebrolisina is and where its research stands, which already puts you ahead of most readers. Four questions remain that no encyclopedia can answer for you, because the answers depend on your own situation:
- What would you measure beforehand, so that later you could tell whether anything actually changed?
- What would you watch along the way, and how consistently?
- What would you ask a professional, and in how much detail, so you do not walk out with a textbook answer?
- What would make you stop?
That is what the course is for
PeptiXtreme is ${CIF.LECCIONES} lessons that hand out no numbers. Each one ends with your starting point, what to watch along the way, the specific questions you take to a professional and the signals that mean stop. It includes per-module exams, a diploma with a verifiable folio, a record to track how you progress, and a human advisor you can actually write to.
See the course → Or measure your judgment, freeReferences
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- Cerebrolysin for acute ischaemic strokereview Cochrane Database Syst Rev · 2023 · PMID 37818733 →
- Cerebrolysin for vascular dementia Cochrane Database Syst Rev · 2019 · PMID 31710397 →
- Cerebrolysin for acute ischaemic stroke Cochrane Database Syst Rev · 2020 · PMID 32662068 →
- Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials Dement Geriatr Cogn Disord · 2015 · PMID 25832905 →
- Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series Neurol Sci · 2021 · PMID 33620612 →
- Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials Neurol Sci · 2017 · PMID 28707130 →
- Speech Therapy Combined With Cerebrolysin in Enhancing Nonfluent Aphasia Recovery After Acute Ischemic Stroke: ESCAS Randomized Pilot Studyhuman Stroke · 2025 · PMID 39957612 →
- Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical usereview Med Res Rev · 2021 · PMID 32808294 →
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for Cerebrolisina or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
Frequently asked questions
What is Cerebrolisina?
A peptide preparation studied for its relationship with neurotrophic factors and neuronal protection and function. It is studied within the area of cognitive.
Is there human evidence for Cerebrolisina?
It is the compound in its group with the most clinical trials and Cochrane reviews, but the overall result is disappointing: the 2023 Cochrane review on acute ischemic stroke concludes with moderate certainty that it probably provides no benefit for mortality, and it detects a possible increase in serious non-fatal adverse effects.
Is it approved by any health agency?
Registered in several Eastern European and Asian countries; not approved by the FDA.
What is the dose of Cerebrolisina?
We do not publish dosages. This is not an oversight. No single figure works for everyone: the regimen depends on a person's medical history, on whatever medication they already take, and on the goal they are chasing, which is something a professional weighs with the case in front of them. What you can build is the ability to walk into that appointment knowing what to ask.
Where can I learn to evaluate this properly?
This page tells you what Cerebrolisina is and what the evidence says. The PeptiXtreme course teaches the other half: what you would measure before considering anything, what you would watch, the specific questions you would take to a professional and when you would stop.